04.06.2015 Views

2012 Scientific Report - Queensland Children's Medical Research ...

2012 Scientific Report - Queensland Children's Medical Research ...

2012 Scientific Report - Queensland Children's Medical Research ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

<strong>Research</strong> Grants and Contracts<br />

Years Grant Agency Chief<br />

Investigators<br />

2010- QCMRI/ Children’s A/Prof. A<br />

2015 Health Foundation Hallahan<br />

<strong>Queensland</strong><br />

Title<br />

Tumour Bank - Infrastructure<br />

Funding<br />

Amount<br />

$401,911<br />

<strong>2012</strong>-<br />

2013<br />

The BrainChild<br />

Foundation<br />

Dr. W Ingram<br />

Towards Better Outcomes For<br />

Children With Brain Tumours –<br />

Advancement Of Multiple <strong>Research</strong><br />

Studies Using Banked Specimens<br />

$25,000<br />

<strong>2012</strong>-<br />

2016<br />

NHMRC Dr A Moore The role of Survivin and XIAP (Xlinked<br />

inhibitor of apoptosis<br />

protein) as biomarkers and<br />

therapeutic targets in paediatric<br />

acute myeloid leukamia<br />

$248,424<br />

<strong>2012</strong>-<br />

2016<br />

Children’s Health<br />

Foundation<br />

<strong>Queensland</strong> / QCMRI<br />

Dr A Moore<br />

A study to assess the mechanisms<br />

of cell death in acute myeloid<br />

leukaemia.<br />

$506,615<br />

<strong>2012</strong> Pfizer Australia Dr A Moore The role of Survivin and XIAP (Xlinked<br />

inhibitor of apoptosis<br />

protein) as biomarkers and<br />

therapeutic targets in paediatric<br />

acute myeloid leukamia<br />

<strong>2012</strong> ANZ Trustees Dr A Moore The role of Survivin and XIAP (Xlinked<br />

inhibitor of apoptosis<br />

protein) as biomarkers and<br />

therapeutic targets in paediatric<br />

acute myeloid leukamia<br />

$50,000<br />

$50,000<br />

Publications<br />

Peer Reviewed Manuscripts<br />

1. Bavetsias V, Crumpler S, Sun C, Avery S, Atrash B, Faisal A, Moore AS, Kosmopoulou M,<br />

Brown N, Sheldrake PW, Bush K, Henley A, Box G, Valenti M, de Haven Brandon A,<br />

Raynaud FI, Workman P, Eccles SA, Bayliss R, Linardopoulos S, Blagg J. Optimization of<br />

imidazo [4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora<br />

kinase inhibitor as an orally bioavailable preclinical development candidate for the<br />

treatment of acute myeloid leukemia. J Med Chem<strong>2012</strong>; 55: 8721-34<br />

QCMRI <strong>Scientific</strong> <strong>Report</strong> <strong>2012</strong> 7

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!